Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BREXAFEMME is an oral small-molecule tablet approved by GSK in June 2021 for an undisclosed indication in women's health. The specific mechanism of action and therapeutic target are not publicly detailed in available data, limiting assessment of its clinical positioning.
Peak12.6 years to LOE
Peak-stage product with no reported competitive pressure suggests stable revenue but limited growth opportunity; team size and hiring likely moderate.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
BREXAFEMME currently shows zero linked job postings, reflecting either a mature, stable team or limited expansion plans. The peak-stage lifecycle and strong patent protection suggest careers on this product offer stability over growth, with emphasis on maintaining market share and maximizing profitability.
Brand ManagerMedical Science Liaison
Worked on BREXAFEMME at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.